| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $58.9M | +120.3% |
| SG&A Expense | $80.4M | +208.3% |
| Operating Income | -$139.3M | -163.8% |
| Pre-tax Income | -$110.2M | -51.1% |
| Income Tax | -$4.5M | -763.1% |
| Net Income | -$105.7M | -43.5% |
| EPS (Basic) | -$0.72 | +2.7% |
| EPS (Diluted) | -$0.72 | +2.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $788.4M | +711.7% |
| Current Assets | $1.25B | +440.6% |
| Total Assets | $1.53B | +442.5% |
| Current Liabilities | $25.5M | +378.7% |
| Total Liabilities | $52.2M | +69.2% |
| Stockholders' Equity | $1.48B | +488.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$82.2M | -114.1% |
| Capital Expenditures | $33.2M | +9333.2% |
| Investing Cash Flow | -$489.7M | -178.6% |
| Financing Cash Flow | $1.26B | +319.1% |
| Free Cash Flow | -$115.4M | -197.8% |